Lucira Health Shares Drop 28% After Big Jump Tuesday
05 1월 2023 - 12:50AM
Dow Jones News
By Chris Wack
Lucira Health Inc. shares were down 28% at 43 cents, one day
after the company said it submitted an Emergency Use Authorization
application to the Food and Drug Administration for
over-the-counter use of its at-home molecular Covid-19 and flu
test.
The stock closed Tuesday's session up 440%, but is still down
63% in the past three months.
Lucira's test for Covid-19 and flu was granted Emergency Use
Authorization for Point-of-Care use in a healthcare setting in
November 2022.
In seeking OTC authorization, Lucira intends to make the test
broadly available to consumers both online as well as in
pharmacies. Lucira said it worked closely with the FDA to complete
additional testing to demonstrate that the test could be used by
consumers at home.
Lucira at-home Covid-19 test users will have access to Lucira
Connect, which allows them to scan their test result with their
smartphone, and if positive, join an immediate and free telehealth
visit to get treatment without leaving home.
Upon authorization of the test, Lucira test users will be able
to learn if they are sick with Covid-19 or influenza, talk to a
doctor about treatment, and access the appropriate prescription
within hours.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 04, 2023 10:35 ET (15:35 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Lucira Health (NASDAQ:LHDX)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Lucira Health (NASDAQ:LHDX)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Lucira Health Inc (나스닥)의 실시간 뉴스: 최근 기사 0
More Lucira Health Inc News Articles